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Guideline development in 
cardiovascular diseases is a well 
developed process in both the 
United States and Europe that has enhanced 
the delivery of proved treatments and improved 
patient outcomes. It most certainly has not gone 
astray.
Guidelines for cardiovascular disease 
Between 1970 and 2000, life expectancy in 
the United States increased by six years,1 with 
nearly two thirds of that increase, 3.9 years, 
due to improved outcomes in cardiovascular 
It is a long time since clinical 
guidelines were seen as cook-
book medicine and a threat 
to professional autonomy. Nowadays, evidence 
based guidelines are considered one of the m ajor 
efforts to improve patient care. Development 
of guidelines has progressed enormously, with 
many organisations (including the National In-
stitute for Health and Clinical Excellence in the 
UK) using validated methods such as the AGREE 
instrument.1 Clinical guidelines are valid if they 
are developed in a rigorous way, independently 
of vested interests of their developers, and if they 
support decision making in practice and affect 
actual care. But are current guidelines meeting 
these criteria? I have concerns.
For guidelines to have an impact on actual 
care, they need to be integrated with other qua-
ity improvement initiatives, such as perform-
ance measurement and quality improvement 
programmes. This requires intensive collabora-
tion between the organisations responsible for 
these tasks,2 which is lacking in most countries. 
Expert guideline developers, usually clinicians 
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diseases and stroke. Half of the improvement 
in coronary heart disease mortality was due 
to improvement in population risk factors; 
the other half could be attributed to improved 
evidence based treatment.2
Unfortunately, proved treatment strategies 
were not consistently applied. Permanent 
pacemakers were definitely justified in less 
than half of patients who received one and not 
justified about 20% of the time.3 Less than half 
of patients presenting with acute myocardial 
infarction who had had a previous event and 
no contraindications were taking aspirin.4 
Angiotensin converting enzyme inhibitors 
were used in less than half of eligible patients 
with heart failure.5 Use of treatments known to 
improve outcomes showed enormous regional 
variations that could not be explained by 
patient differences.6
In response to these concerns, the American 
College of Cardiology and American Heart 
Association started developing clinical 
practice guidelines 25 years ago. The European 
Society of Cardiology followed not long 
aims and interests from those in the quality 
improvement world. Stakeholders use guidelines 
for different purposes, also hindering integration 
and improvement. For instance, policy makers 
and authorities want to use them for inspection 
or to contain costs, whereas professional bodies 
may use them to strengthen their position in the 
competition with other disciplines.
Another problem is that many guidelines still 
do not meet the internationally accepted criteria 
of the AGREE instrument.1 A recent evaluation of 
seven depression guidelines from different coun-
tries (five of which were issued after the AGREE 
instrument was published in 2003) showed 
scores of 25-63% for stakeholder involvement, 
1-64% for rigour of development, 0-56% for 
applicability, and 8-75% for editorial independ-
ence.3 New (still unpublished) evaluations of 
guideline quality show similar findings.
Local influence
Guideline developers are aware that there is a 
risk of bias in recommendations because appro-
priate evidence is often lacking. However, even 
when evidence is available, the final recommen-
dations often reflect personal opinions, local 
culture, or vested interests of the developers.4-6 
A recent Institute of Medicine analysis reports 
many examples of undue industry influence on 
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thereafter. The American groups have also 
used their experience to produce instructions 
on how to write rigorous guidelines.7
Is there evidence that the implementation of 
practice guidelines led to changes in clinical 
practice that have improved patient outcomes? 
Yes.
A project to apply the guidelines improved 
the delivery of evidence based care in 
10 hospitals in southeastern Michigan.8 
Guideline based care reduced mortality at 30 
days by 4.9% and at one year by 5.1%.9 The 
Global Registry of Acute Coronary Events, 
a multinational cohort study across 14 
countries,10 examined the use of guideline 
based treatment in 44 372 patients with ST 
elevation myocardial infarction or non-ST 
elevation acute coronary syndromes. Use 
of drug treatments recommended by both 
the US and European guidelines increased  
significantly, and this was associated with 
improved patient outcomes. In ST elevation 
patients, death decreased by 3.9% and 
cardiogenic shock by 2.4%; in patients with 
acute coronary syndrome hospital death 
decreased by 0.7% and death between hospital 
discharge and six month follow-up by 1.6%.
In the United States, the Center for Medicare 
and Medicaid Services sought to improve 
the delivery of guideline based therapy 
by publicly reporting compliance data for 
individual hospitals. Between 2000 and 2005, 
compliance with guideline recommended 
care for myocardial infarction improved from 
77.5% to 93.5% and inpatient mortality after 
a heart attack decreased from 103.8/1000 
admissions to 81.7/1000.11
Minnesota has its own guideline 
development process and quality 
improvement programme that predates the 
national effort.12 Performance measures 
for outpatient care are publicly reported 
for all medical practices within the state. 
Cardiovascular mortality in Minnesota fell by 
35% from 1995 to 2005 and is now the lowest 
of any state.
Development is key
Given this record of success, what are the 
arguments against guidelines? Firstly, there 
is concern that many guidelines are based on 
expert opinion rather than firm evidence.13 
We agree this is a problem, but the solution 
is to develop more evidence, not to ignore 
existing evidence and expert consensus. The 
process used for developing guidelines is also 
not always perfect—that is, not all guidelines 
are created equal. However, various groups 
the development of clinical practice guidelines 
and makes recommendations to limit conflicts of 
interests.6 Guideline developers sometimes have 
close ties with the industry. 7 Another problem is 
that current methods for translating evidence and 
professional experiences into recommendations 
for practice have got less attention and are much 
less sound and transparent than the methods for 
finding and grading evidence.
Guideline developers in different countries 
often come up with different advice, partly 
because they prefer to use local evidence and 
partly because normative and cultural opinions 
have a substantial role in defining good care.8 9 
This lack of independence and inconsistencies in 
different guidelines lower the trust that potential 
users might place in them.
Lack of applicability
Statements on clinical effectiveness dominate 
guidelines and assume “ideal patients” without 
comorbidities. They often do not adequately 
address issues relevant for everyday care, such 
as safety and risk management, multidisci-
plinary collaboration, effect on costs or com-
pliance, and patient self management. The 
analysis of the seven depression guidelines, 
for example, showed a focus on drug treatment 
and limited attention to psychological therapies, 
suicide risk, and social issues.3 In reality half of 
patients with a chronic condition have at least 
two problems that may interact, requiring com-
plex care and support.10 But guidelines are often 
formulated by mono-disciplinary specialists 
with specific patient types in mind. Patient and 
public involvement in guideline development 
is of growing interest but not standard practice 
yet, and it is not clear how to incorporate their 
preferences.11 12
Despite examples of good uptake, audits 
around the world show that guidelines are, on 
average, used in only 50-70% of day to day deci-
sions and variation in performance is large.13 At 
least part of the reason for this is that some of the 
guidelines have limited relevance to clinicians 
and patients, are written as a handbook and not 
as a concise set of recommendations for prac-
tice (maximum 5-10), or are incompatible with 
the norms and values of target users.14 This may 
make implementation ineffective, particularly 
when it requires new behaviour and organisa-
tional change.15
Value for money
Finally, guideline development is time con-
suming and expensive (€150 000 (£130 000; 
$220 000) to €200 000 per guideline in the 
Netherlands, and more than £400 000 for a NICE 
guideline). The investments may be worth while 
if guidelines are clinically relevant and have a 
wide impact on health care. However, the cost 
effectiveness of guideline development com-
pared with other methods for improving patient 
care is unknown.
Guidelines may thus be important for improv-
ing patient care, but changes are needed to make 
them more relevant and effective. Collaboration 
between all stakeholders—relevant clinicians, sci-
entists, patients, policy makers, quality improve-
ment experts, and others—is essential to identify 
clinical questions, assess the evidence, draw up 
workable recommendations and develop related 
indicators of improved quality of care and pro-
grammes for implementation. Procedures must 
be changed to speed up the development, mini-
mise personal bias in recommendations, and 
involve patients more actively in the process of 
both developing and using guidelines. With-
out such changes, guideline development may 
increasingly be seen as an expensive but unhelp-
ful and ineffective toy for a happy few.
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have set out recommendations that lead to 
sound and effective guidelines, as the US 
cardiovascular disease example shows.14 One 
of these recommendations is to take steps to 
ensure that relationships with industry do not 
contaminate the development process.15 
Some clinicians resent the intrusion of 
guidelines on their practice.16 However, 
guidelines are just that—guidelines; they are 
not meant to replace patient centred decision 
making, particularly for very elderly patients 
and those with multiple comorbidities.15
The process for development of 
cardiovascular clinical practice guidelines is 
itself an ongoing quality improvement effort. 
Guidelines are a repository of information 
for the clinician, recommending the use of 
treatments that have been proved effective 
and not using treatments that are ineffective 
and may be harmful. The goal of clinical 
practice guidelines is to improve the practice 
of medicine, the quality of care, and patient 
outcomes. Cardiovascular clinical practice 
guidelines are already a success story. We 
believe that the cardiovascular clinical 
practice guidelines effort is consistent with 
the highest ideals of medicine, and have felt 
privileged to have a role in its leadership.
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